Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Pancreatic Neoplasms × pembrolizumab × Clear all

Phase

Status

Completed 25 Recruiting 15 Active not recruiting 13 Terminated 9 Withdrawn 5 Unknown 5 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 10 Triple Negative Breast Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 7 Head and Neck Neoplasms 5 Turcot syndrome 3 Prostatic Neoplasms 3 Neoplasm Metastasis 3 Lung Neoplasms 3 Carcinoma, Renal Cell 3 Breast Neoplasms 3 Uterine Cervical Neoplasms 2 Hodgkin Disease 2 Glioblastoma 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Hepatocellular 2 Biliary Tract Neoplasms 2 Advanced Endometrial Cancer 2 Vulvar Neoplasms 1 To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1 Thyroid Neoplasms 1 Thoracic Neoplasms 1 Stomach Neoplasms 1 Squamous NSCLC 1 Solid Tumors 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Rare Tumour 1 Primary Glioblastoma 1

Interventions

Gemcitabine 17 irinotecan sucrosofate 7 Oxaliplatin 6 Leucovorin 6 Fluorouracil 6 130-nm albumin-bound paclitaxel 6 Taxes 4 Drug Therapy 4 toripalimab 3 S 1 (combination) 3 Radiosurgery 3 Injections 3 Albumin-Bound Paclitaxel 3 surufatinib 2 Paclitaxel 2 Irinotecan 2 Capecitabine 2 Blood Specimen Collection 2 Biopsy 2 zimberelimab 1 sintilimab 1 potassium oxonate 1 pembrolizumab 1 nimotuzumab 1 netrin-1 inhibitor NP137 1 gimeracil 1 folfirinox 1 disitamab vedotin 1 defactinib 1 camrelizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04901741 2025-06-27

OPTIMUS

TME Pharma AG

Phase 2 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡